DK0625195T3 - Behandling af centralnervesystemet med genetisk modificerede celler - Google Patents
Behandling af centralnervesystemet med genetisk modificerede cellerInfo
- Publication number
- DK0625195T3 DK0625195T3 DK92925278T DK92925278T DK0625195T3 DK 0625195 T3 DK0625195 T3 DK 0625195T3 DK 92925278 T DK92925278 T DK 92925278T DK 92925278 T DK92925278 T DK 92925278T DK 0625195 T3 DK0625195 T3 DK 0625195T3
- Authority
- DK
- Denmark
- Prior art keywords
- nervous system
- central nervous
- treatment
- genetically modified
- modified cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79289491A | 1991-11-15 | 1991-11-15 | |
PCT/US1992/009896 WO1993010234A1 (en) | 1991-11-15 | 1992-11-13 | Therapy of central nervous system by genetically modified cells |
CA002095300A CA2095300C (en) | 1991-11-15 | 1993-04-30 | Use of genetically modified cells to treat defects, disease or damage of the central nervous system |
JP5136554A JPH06329559A (ja) | 1991-11-15 | 1993-05-14 | 遺伝子的に修飾された細胞を移植して中枢神経系における欠陥、疾病、あるいは損傷を治療するための方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0625195T3 true DK0625195T3 (da) | 1999-08-30 |
Family
ID=27169416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92925278T DK0625195T3 (da) | 1991-11-15 | 1992-11-13 | Behandling af centralnervesystemet med genetisk modificerede celler |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0625195B1 (da) |
JP (1) | JPH06329559A (da) |
AT (1) | ATE175442T1 (da) |
CA (1) | CA2095300C (da) |
DE (1) | DE69228127T2 (da) |
DK (1) | DK0625195T3 (da) |
ES (1) | ES2126606T3 (da) |
GR (1) | GR3029362T3 (da) |
WO (1) | WO1993010234A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103226A (en) * | 1994-08-12 | 2000-08-15 | Arch Development Corporation | Genetically engineered cells that produce produce L. Dopa |
US6204053B1 (en) | 1994-11-08 | 2001-03-20 | Diacrin, Inc. | Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
US6294383B1 (en) | 1994-11-08 | 2001-09-25 | The Mclean Hospital Corporation | Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases |
CA2210718A1 (en) | 1995-01-17 | 1996-07-25 | Genetic Therapy, Inc. | Delivery of therapeutic agents by gene therapy |
US5753505A (en) * | 1995-07-06 | 1998-05-19 | Emory University | Neuronal progenitor cells and uses thereof |
CA2305787A1 (en) | 2000-05-09 | 2001-11-09 | The University Of British Columbia | Cxcr4 antagonist treatment of hematopoietic cells |
CA2245224A1 (en) | 1998-08-14 | 2000-02-14 | Jiang-Hong Giong | Chemokine receptor antagonists and chemotherapeutics |
AU762472B2 (en) | 1998-03-13 | 2003-06-26 | University Of British Columbia, The | Therapeutic chemokine receptor antagonists |
US6444205B2 (en) | 1998-09-30 | 2002-09-03 | Diacrin, Inc. | Transplantation of neural cells for the treatment of chronic pain or spasticity |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
AU780754B2 (en) * | 1999-03-04 | 2005-04-14 | Revivicor Inc | Genetic modification of somatic cells and uses thereof |
US20010038836A1 (en) * | 2000-04-04 | 2001-11-08 | Matthew During | Application of myeloid-origin cells to the nervous system |
US7378098B2 (en) | 2000-04-12 | 2008-05-27 | The University Of British Columbia | CXC chemokine receptor 4 agonist peptides |
US7368425B2 (en) | 2006-03-24 | 2008-05-06 | Chemokine Therapeutics Corp. | Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis |
US20050059584A1 (en) | 2002-08-16 | 2005-03-17 | Ahmed Merzouk | Novel chemokine mimetics synthesis and their use |
US20030124095A1 (en) | 2001-12-31 | 2003-07-03 | Regents Of The University Of California | Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
KR101226702B1 (ko) * | 2010-10-08 | 2013-01-25 | 충북대학교 산학협력단 | 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도 |
WO2020018700A1 (en) | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0378576B1 (en) * | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US6511823B1 (en) * | 1990-08-20 | 2003-01-28 | American Cyanamid Corporation | Heparin binding neurotrophic factor gene sequence |
AU9076191A (en) * | 1990-11-21 | 1992-06-25 | Massachusetts Institute Of Technology | Mice having beta 2 microglobulin gene disruption |
-
1992
- 1992-11-13 WO PCT/US1992/009896 patent/WO1993010234A1/en active IP Right Grant
- 1992-11-13 DE DE69228127T patent/DE69228127T2/de not_active Expired - Lifetime
- 1992-11-13 ES ES92925278T patent/ES2126606T3/es not_active Expired - Lifetime
- 1992-11-13 DK DK92925278T patent/DK0625195T3/da active
- 1992-11-13 AT AT92925278T patent/ATE175442T1/de not_active IP Right Cessation
- 1992-11-13 EP EP92925278A patent/EP0625195B1/en not_active Expired - Lifetime
-
1993
- 1993-04-30 CA CA002095300A patent/CA2095300C/en not_active Expired - Fee Related
- 1993-05-14 JP JP5136554A patent/JPH06329559A/ja active Pending
-
1999
- 1999-02-10 GR GR990400449T patent/GR3029362T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2095300C (en) | 2002-06-25 |
CA2095300A1 (en) | 1994-10-31 |
EP0625195B1 (en) | 1999-01-07 |
JPH06329559A (ja) | 1994-11-29 |
ES2126606T3 (es) | 1999-04-01 |
WO1993010234A1 (en) | 1993-05-27 |
DE69228127T2 (de) | 1999-09-02 |
DE69228127D1 (de) | 1999-02-18 |
ATE175442T1 (de) | 1999-01-15 |
GR3029362T3 (en) | 1999-05-28 |
EP0625195A1 (en) | 1994-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0625195T3 (da) | Behandling af centralnervesystemet med genetisk modificerede celler | |
DE68929077D1 (de) | Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems | |
DK0918848T3 (da) | Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA | |
NO166943C (no) | Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider. | |
NO874393L (no) | Fremgangsmaate for nedsetting av paaler i grunnen, samt apparat for utfoerelse av fremgangsmaaten. | |
DK193788A (da) | Fremgangsmaade til isolering af nucleinsyrer | |
GB2136814B (en) | Dna vectors | |
ATE88097T1 (de) | Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut. | |
SE8000435L (sv) | N-bensylimidazoler med selektivt inhiberande verkan pa tromboxansyntetasenzymet jemte farmaceutiska beredningar innehallande sadana n-bensylimidazoler och sett for deras framstellning | |
DE69018045D1 (de) | Pfropfcopolymer, das Pfropfcopolymer enthaltende Lösung und Verfahren zum Behandeln von Kontaktlinsen. | |
Amarenco | Gerard Amarenco, MD | |
NO870493D0 (no) | Fremgangsmaate og apparat for fluidumsirkulasjon ved hjelp av pumping. | |
DK0533849T3 (da) | Sucrosephosphatsyntase (SPS), fremgangsmåde til dens fremstilling, dens cDNA og anvendelse af cDNA til at ændre ekspression | |
ATE66478T1 (de) | 12- und 13-substituierte ergolinderivate. | |
FI891020A0 (fi) | Menetelmä proteaasi-inhibiittoriaktiivisuutta omaavien egliinimutanttien valmistamiseksi | |
ATE195547T1 (de) | Antioxidantzusammensetzung und verfahren zu dessen herstellung | |
ATE60190T1 (de) | Verfahren zum regenerieren von mais. | |
MX9302761A (es) | Metodo de sintesis de monomeros de nucleotido. | |
DK0399545T3 (da) | Fremgangsmåde til dekontaminering af mycoplasmaholdige cellekulturer | |
Jamieson | An application of Morita techniques in a university counseling center setting. | |
Prince | Commentary on four papers on psychiatry and religion. | |
RU96112053A (ru) | Способ лечения детей, больных ювенильным ревматоидным артритом | |
IT8248415A0 (it) | Coloranti azo-stilbenici, in particolare per tingere cuoio, e procedimento per la loro produzione | |
BG49441A1 (en) | 1- phenil- n- (2- chlorethylcarbamoil)- 7, 8- dimetoxy- 2, 3, 4, 5- tetrahydro- 1h- 3- benzazepini and method for their preparation | |
NO892594D0 (no) | Fremgangsmaate til innfoering og binding av gass i vann, apparat for gjennomfoering av fremgangsmaaten og vann fremstilt ved fremgangsmaaten. |